Use this report to: - Analyze the global prostate cancer market, with important statistics and analysis on existing drugs, and diagnostic technologies. - Receive information on regulatory environment, prostate cancer staging, diagnostic strategies and technologies, and prostate cancer incidence. - Quantify the testing, screening technology and therapeutics markets for prostate cancer along with utilization of the various therapeutic and diagnostic modalities for its prevention and treatment. - Receive information on the types of treatment strategies for the clinical management of prostate cancer.
Highlights - The global market for prostate cancer products reached nearly $47.2 billion in 2016 and should reach nearly $65.1 billion in 2021, with a compound annual growth rate (CAGR) of 6.6%. - Diagnosis and screening as a segment reached $19.3 billion in 2016 and should reach $27.4 billion in 2021, with a CAGR of 7.2 %. - Surgical and radiation therapy as a segment reached nearly $14.4 billion in 2016 and should reach $20.8 billion 2021, with a CAGR of 7.7%.
Introduction & Scope
Study goals and objectives This report provides an overview of the current and potential global market for prostate cancer treatments and testing technologies. The key objective is to present a comprehensive analysis of the current state of prostate cancer therapy and technology, utilization of the various therapeutic and diagnostic modalities to prevent and treat prostate cancer. The report’s focus is on prostate cancer treatment strategies such as hormone therapy, chemotherapy, radiotherapy and immunotherapy, and other treatment modalities and testing and screening methods. The report also includes an overview of prostate cancer staging, diagnostic strategies and technologies. Important trends in the field of prostate cancer research and development have been reviewed in this report, and sales forecasts by treatment and screening categories are provided through 2021. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the prostate cancer market.
Reasons for doing this study This study was conducted to provide detailed information regarding screening, testing and treatment options for prostate cancer. There is an increasing need for new and innovative technologies. This industry is experiencing growth. The use of new drug delivery technologies for prostate cancer has increased in the past few years. This study looks at most types of treatment strategies for the clinical management of prostate cancer. This BCC Research market research report will increase the awareness of current and emerging drugs and technologies for prostate cancer, including hormone therapy, chemotherapy, radiation therapy, surgical therapy, immunotherapy and also nutrition therapy.
Intended audience This report is an exhaustive study on the global prostate cancer market, with important statistics and analysis on existing drugs, and diagnostic technologies, latest trends, market structure, market size, key drug segments and trends in technology. This study contributes to the areas of market growth in prostate cancer prevention and treatment strategies from the point of view of manufacturers, product suppliers, healthcare providers and consumers of prostate cancer products and services. This study will be of interest largely to the pharmaceutical and biotechnology industries, as well as clinics, hospitals and research institutes. This report may also prove crucial for investment firms in the concerned sector. This report shows tests currently being used for prostate cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies. The report provides market data for 2012 to 2021 and also covers commercial prospects for prostate cancer diagnostic assays, current tests in use and their future.
Scope of report The scope of this study is testing, screening technology and also therapeutics markets for prostate cancer. The report also includes the regulatory environment, current technologies, new technologies, prostate cancer incidence, market projections and market share, along with latest trends and new developments. Screening for diagnosis, therapy via drug, surgery or radiation is measured and broken down by PSA testing, digital rectal exam (DRE), prostate biopsy, hormone therapy, chemotherapy, immunotherapy, external beam radiation therapy (EBRT), prostatectomy and brachytherapy.
Our reports have been used by over 10K customers, including:
134 pages •
By Infiniti Research Limited
• Apr 2018
About Prostate Cancer Testing Prostate cancer testing refers to the tests conducted for the detection, localization, grading, and staging of prostate carcinoma. The currently established methods of prostate cancer detection include digital rectal examination (DRE), serum prostate-specific antigen (PSA) tests, and transrectal...
339 pages •
By Global Industry Analysts
• Apr 2018
This report analyzes the worldwide markets for Prostate Cancer Therapeutics in US$ Million by the following Segments: Hormone Therapy, and Other Therapies. The report provides separate comprehensive analytics for the US, Canada, Europe, and Rest of World. Annual estimates and forecasts are provided for the period...
Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Hormone-Sensitive Prostate Cancer clinical trials scenario. This report provides...
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Metastatic Prostate Cancer clinical trials scenario. This report provides top line data relating...
PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2026 Summary Prostate cancer (PCa) is the second most common cancer in men worldwide, after skin cancer. It accounts for 12% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While...